NeuroScientific Biopharmaceuticals reported an 80% clinical response rate [1] for its StemSmart cell therapy targeting Crohn’s disease on Tuesday.
This development suggests a potential new avenue for treating inflammatory bowel disease, which often resists standard medical interventions. If the results scale, stem cell therapy could provide a more durable alternative to long-term immunosuppressant drugs.
The company said that all five patients [2] who participated in the program showed clinical improvement. The 80% response rate [1] is based on the specific clinical parameters established for the StemSmart program.
Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. Current treatments typically focus on managing symptoms or reducing inflammation through medication, and surgery. The StemSmart therapy aims to utilize stem cells to modify the immune response or repair damaged tissue.
NeuroScientific Biopharmaceuticals said the program was designed to demonstrate the efficacy of the therapy in a controlled setting. While the sample size is limited to five individuals [2], the company said that every patient in the cohort experienced a positive outcome.
Further trials will be necessary to determine if these results are reproducible across a larger and more diverse patient population. The company has not yet released detailed data regarding the long-term sustainability of the clinical response, or the specific metrics used to calculate the 80% rate [1].
“NeuroScientific Biopharmaceuticals reported an 80% clinical response rate for its StemSmart cell therapy.”
The reported success in a very small cohort provides a proof-of-concept for StemSmart, but the limited sample size of five patients means the results are not yet statistically significant. The gap between a 100% improvement rate in patients and an 80% clinical response rate suggests that the company is using a specific technical threshold to define 'response' rather than simple patient improvement.
